TARRYTOWN, N.Y., March 11, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (REGN) announced the U.S. Food & Drug Administration (FDA) has extended the approval of Praluent ® (alirocumab) as ...

The Food and Drug Administration on Tuesday approved a once-monthly dose form of the cholesterol drug Praluent. The drug, co-developed by Regeneron Pharmaceuticals and Sanofi, first earned FDA ...

Regeneron Pharmaceuticals, Inc. REGN announced that the FDA extended the approval of the cholesterol drug Praluent’s (alirocumab) label. The regulatory body approved the drug as an adjunct to diet and ...

The dosage of Praluent for pediatric patients aged 8 years and older with HeFH is based on body weight and can be adjusted based on LDL-C lowering response. The Food and Drug Administration (FDA) has ...

Praluent has a list price of more than $14,000 a year. However, Express Scripts customers will be able to receive the drug for $4,500 to $6,600 annually after discounts and rebates, Express Scripts ...

PARIS, July 9 (Reuters) - French drugmaker Sanofi and U.S. partner Regeneron said the results of a late-stage study of their Praluent injection in Japan showed the drug reduced "bad cholesterol" among ...

LONDON, July 24 (Reuters) - A new type of cholesterol drug from Sanofi and Regeneron Pharmaceuticals won a green light from European regulators on Friday, two months behind a rival product from Amgen.

Since their PCSK9 drugs to lower bad cholesterol won FDA approvals a month apart in the summer of 2015, Amgen and Regeneron have waged a war for supremacy in the market—with the California-based ...

Up to 10 million Americans will soon have a new option for lowering their cholesterol – at a price of $14,600 a year. The Food and Drug Administration surprised much of the medical community Friday by ...